Neogene Therapeutics is a pre-clinical stage biotechnology company pioneering the development of next-generation, fully personalized engineered T cell therapies for a broad spectrum of cancers. The Company’s engineered T cells target tumor-specific mutation-derived neo-antigens, that render tumor cells vulnerable to detection and destruction by T cells. Neogene’s proprietary technology platform aims to identify T cell receptor genes with specificity for neo-antigens from tumor biopsies. Neogene’s novel approach intends to deliver a tailored set of T cell receptor genes for each individual patient, which will be engineered into patient-derived T cells directing them towards neo-antigens in tumor cells, with the goal of providing a fully personalized engineered T cell therapy for cancer.

The Online Custom Vector Onboarding Process Consists of 5 General Steps: 1. Uploading your vector sequence 2. Answering questions regarding your vector 3. Selecting the insertion site(s) 4. Review and approval of your selection 5. Completing your order

In my laboratory, we are advancing research to elucidate the mechanism of action of functional ingredients in foods by focusing on the molecular interactions between food molecules and human molecules to clarify the mechanism of action of functional components in food, targeting the positive functions (antibacterial, antiviral, anticancer, antioxidant, antiglycation) and negative functions (carcinogenesis, allergenicity) of food. An important step in such research is to utilize recombinant proteins to clarify the function and structure of target proteins. In this talk, I will show examples of the use of artificial genes, which are useful tools for the expression of recombinant proteins, as well as examples of future applications.